Skip to content

Serotonin: all studies

Page 343 of 401: studies 3,421 to 3,430 of 4,004, newest first. Back to the serotonin overview

Research

Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study

PLoS One August 8, 2012 José Carlos Bouso, Débora González, Sabela Fondevila et al. 313 citations

Ayahuasca is an Amazonian psychoactive plant beverage containing the serotonergic 5-HT(2A) agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting alkaloids (harmine, harmaline and tetrahydroharmine) that render it orally active. Ayahuasca ingestion is a central feature in several Brazilian syncretic churches that have expanded their activities to urban Brazil, Europe and North...

DOI: 10.1371/journal.pone.0042421 (opens in new tab) Ayahuasca Psychopathology Hallucinogen Impulsivity +2

(±)3,4-methylenedioxymethamphetamine ("ecstasy") treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain.

The Journal of Comparative Neurology August 1, 2012 Ann M. Hemmerle, Jonathan W. Dickerson, Nicole R Herring et al. 29 citations

(±)3,4-Methylenedioxymethamphetamine (MDMA), a widely used drug of abuse, rapidly reduces serotonin levels in the brain when ingested or administered in sufficient quantities, resulting in deficits in complex route-based learning, spatial learning, and reference memory. Neurotrophins are important for survival and preservation of neurons in the adult brain, including serotonergic neurons. In...

DOI: 10.1002/cne.23048 (opens in new tab) Full text (opens in new tab) Substantia nigra Hippocampus Neostriatum Cerebral cortex +16

Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice

Psychopharmacology July 28, 2012 J. Moreno, Terrell Holloway, Adrienne Umali et al.

In schizophrenia patients, optimal treatment with antipsychotics requires weeks to months of sustained drug therapy. However, single administration of antipsychotic drugs can reverse schizophrenia-like behavioral alterations in rodent models of psychosis. This raises questions about the physiological relevance of such antipsychotic-like activity. This study evaluates the effects of chronic...

A prospective study of learning, memory, and executive function in new MDMA users

Addiction July 26, 2012 Daniel Wagner, Benjamin Becker, Philip Koester et al. 54 citations

Abstract Aims It is still unclear if cognitive abnormalities in human 3,4‐methylenedioxymeth‐amphetamine ( MDMA ) users existed before the beginning of use or if other confounders could explain the deficits. The present study was conducted in order to assess the relationship between beginning MDMA use and subsequent cognitive performance and to overcome previous methodological shortcomings....

Lost in translation: preclinical studies on 3,4‐methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans

British Journal of Pharmacology July 1, 2012 Ar Green, MV King, SE Shortall et al.

3,4‐Methylenedioxymethamphetamine (MDMA) induces both acute adverse effects and long‐term neurotoxic loss of brain 5‐HT neurones in laboratory animals. However, when choosing doses, most preclinical studies have paid little attention to the pharmacokinetics of the drug in humans or animals. The recreational use of MDMA and current clinical investigations of the drug for therapeutic purposes...

Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 10, 2012 Daniel I. Brierley, Colin Davidson 133 citations

Ayahuasca is a hallucinogenic botanical mixture originating in the Amazon area where it is used ritually, but is now being taken globally. The 2 main constituents of ayahuasca are N,N-dimethyltryptamine (DMT), a hallucinogen, and harmine, a monoamine oxidase inhibitor (MAOI) which attenuates the breakdown of DMT, which would otherwise be broken down very quickly after oral consumption. Recent...

Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats

Drug and Alcohol Dependence June 3, 2012 Pai-Kai Huang, Shawn. M. Aarde, D. Angrish et al. 74 citations

BACKGROUND Reports from US, UK and European drug policy entities, and ongoing media accounts, show increasing recreational use of 4-methylmethcathinone (4-MMC, mephedrone) and 3,4-methylenedioxypyrovalerone (MDPV). Severe sympathomimetic symptoms, hallucinations, psychoses, and even deaths have been reported, yet little scientific information is available on the effects of these compounds in...

A Comparative Review of the Neuro-Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness: The Uniqueness of Some Hallucinogens

NeuroQuantology June 1, 2012 Ümit Sayın 17 citations

Altered states of consciousness induced by hallucinogens (H-ASC) is still a vaguely understood phenomenon. Taken the diverse psychological effects they exert, the main mechanism of action of hallucinogens; LSD, ibogaine, THC, PCP, MDMA, methamphetamine, mescaline, psilocybin and DMT, of which psychological effects are discussed in the article, are not properly understood and explained by the...

Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.

Psychopharmacology June 1, 2012 Adam L. Halberstadt, David E Nichols, Mark A. Geyer 55 citations

Ayahuasca is a psychoactive tea prepared from a combination of plants that contain a hallucinogenic tryptamine and monoamine oxidase inhibitors (MAOIs). Behavioral pattern monitor (BPM) experiments demonstrated that the combination of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and a behaviorally inactive dose of an MAO(A) inhibitor such as harmaline or clorgyline induces biphasic effects on...

DOI: 10.1007/s00213-011-2616-6 (opens in new tab) Full text (opens in new tab) Neuropharmacology Drug metabolism Behavioral effects Pharmacological research

Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study

PLoS One May 4, 2012 Cédric M. Hysek, Linda D. Simmler, V.g. Nicola et al. 158 citations

UNLABELLED: This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the effects of 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects. The clinical study used a double-blind, randomized, placebo-controlled, four-session, crossover design. In vitro, duloxetine blocked the release of both 5-HT and NE...